In line with the cost savings program previously announced (Oct 22, 2025), Q-linea is implementing a streamlined organisation aimed at strengthening its commercial focus and improving operating efficiency. As a result, headcount will be reduced by 16 employees as of January 1, 2026 compared with the reported level of 83 ending Q3 2025. These reductions are limited to Sweden; operations in the US and Italy remain unaffected and continue to support ongoing customer needs.

Ylva Molin, currently Manager of Assay Development, joins the EMG with 13 years of experience at Q-linea, having led several critical development projects and teams.

CFO Christer Samuelsson will leave the company following the onboarding and orderly transition to a new CFO, expected during the first half of 2026.

Jonas Melin, who has led the Research and Development team for nearly 10 years, will transition from his EMG role on January 1, 2026, and continue to provide core expertise in a senior advisory capacity.

“These changes reflect the continued evolution of the Q-linea team as we accelerate our commercial strategy and focus our development portfolio”, says Q-linea CEO Stuart Gander. “I would like to thank both Jonas, who has been a pivotal leader of our scientific and technological progress, and Christer, who has successfully guided the company through a critical period of financial development. Both have elected to rebalance time for other projects. We are pleased to welcome Ylva to the senior leadership team – her deep experience with ASTar application development will be highly valuable as we move into the next phase of our journey.”